Shares of Grace Therapeutics Inc. (GRCE) reached a 52-week high of $4.12 during intraday trading yesterday, which reflects a gain of nearly 65% over the past three months.
Grace Therapeutics, a late-stage biopharmaceutical company focused on rare diseases, is advancing its lead clinical candidate, GTx-104, a novel injectable formulation of nimodipine, in the treatment of aneurysmal Subarachnoid Hemorrhage (aSAH).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com